# TME Pharma Details TMS Exclusive Talks for NOX-A12 With €150,000 Fee and €100 Million Milestones > TME Pharma set out binding and non-binding terms of its TMS talks for NOX-A12, including a €150,000 exclusivity fee and more than €100 million in potential milestones. - Published: 2026-11-10T07:47:52+00:00 - Section: Partnerships - Author: News Desk - URL: https://newsforagent.com/news/2026-11-10/tme-pharma-tms-nox-a12-exclusive-negotiation - Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3399168/0/fr/tme-pharma-fournit-davantage-de-d%C3%A9tails-sur-l-accord-de-n%C3%A9gociation-exclusif-conclu-avec-tms-co-ltd-concernant-le-nox-a12.html) ## Key takeaways - TME Pharma signed a six-month exclusive negotiation agreement with TMS Co., Ltd. on October 29, 2026, with a non-refundable €150,000 exclusivity fee. - Short-term payments to TME Pharma of about €10 million depend on a definitive agreement, with roughly half in cash and half as an equity stake of up to 20% in the subsidiary. - Milestone payments could exceed €100 million, including about €37 million tied to regulatory steps, plus tiered royalties of 8% to 10% on net sales. TME Pharma has published further terms of the exclusive negotiation agreement and non-binding letter of intent it signed with Japan's TMS Co., Ltd. on October 29, 2026 for NOX-A12, including a six-month exclusivity period and a non-refundable €150,000 fee. The Berlin biotechnology company announced the details in a [GlobeNewswire release](https://www.globenewswire.com/news-release/2026/11/10/3399168/0/fr/tme-pharma-fournit-davantage-de-d%C3%A9tails-sur-l-accord-de-n%C3%A9gociation-exclusif-conclu-avec-tms-co-ltd-concernant-le-nox-a12.html) on November 10, 2026. ## What Binds TME Pharma and TMS [TME Pharma](https://akta.pro/company-profiles/0002hzu/tme-pharma) said the six-month exclusivity period and the €150,000 fee are binding. The period can be extended by up to three months for a non-refundable payment of €50,000 per month. The economic terms serve as a basis for talks toward a definitive licence agreement and are not binding. A definitive agreement would take effect only once TMS's Japanese subsidiary has secured sufficient financing to resume the GLORIA trial. Short-term payments to TME Pharma of about €10 million depend on that signature, with roughly half expected in cash and half as a stake in the subsidiary of up to 20%. Milestone payments could exceed €100 million, of which about €37 million relates to regulatory steps toward marketing authorisation, with the first payment possible no earlier than two years out. Tiered royalties of 8% to 10% on net sales and a share of potential sublicence revenue could be added later. TMS is the Japanese biotech that signed the October 29 exclusive negotiation agreement with TME Pharma for the glioblastoma drug, paying €150,000 for six months of exclusivity, according to GlobeNewswire. "We are delighted to collaborate with Mr. Wakabayashi and TMS Co., Ltd.," said Diede van den Ouden, CEO of TME Pharma. "TME Pharma will be actively involved in supporting the subsidiary in its discussions with investors, particularly venture capital firms, both in Japan and abroad." Takuro Wakabayashi, CEO of TMS Co., Ltd., said the companies concluded the agreement with the aim of obtaining the financing needed to resume the GLORIA study. ## TME Pharma's GLORIA Data and Market Estimate According to akta.pro [company records](https://akta.pro/company-data), TME Pharma published GLORIA Phase 1/2 expansion Arm A results in Nature Communications in April 2026, reporting median overall survival of 19.9 months versus 9.5 months for standard of care, with p=0.003, for NOX-A12 plus radiotherapy and bevacizumab in newly diagnosed MGMT-unmethylated glioblastoma. The same records list 17 funding rounds, the most recent a post-IPO debt round of $580,716 in August 2025. TME Pharma estimates the first-line glioblastoma market in the United States and the EU-27 at about €3 billion a year at the time of a NOX-A12 launch, rising to about €4 billion a year by 2046. Assuming a market share of about half of chemotherapy-refractory patients, the company estimates annual revenue of about €1 billion around 2040. ## How the TMS Talks Followed Two Suitors On August 24, 2026, TME Pharma said it had narrowed its search for a partner for NOX-A12 to two suitors in the final evaluation phase of advanced discussions, FierceBiotech reported. The same day, a company update said TME Pharma had entered the final evaluation phase of discussions with two potential partners to license NOX-A12 for glioblastoma treatment, FinanzNachrichten.de reported. On October 29, 2026, TME Pharma signed the exclusive negotiation agreement with TMS Co., Ltd., paying €150,000 for six months of exclusivity, GlobeNewswire reported. ## TME Pharma's Financing Before a TMS Deal TME Pharma said on October 26, 2026 that it had extended its debt maturity to June 30, 2028 and obtained two new bonds, with an additional €1 million in financing available at the company's discretion. The company said its financial visibility through the second quarter of 2028 does not depend on a possible transaction with TMS Co., Ltd. ## Companies in this story - [TME Pharma company profile](https://akta.pro/company-profiles/0002hzu/tme-pharma) · website: https://www.tmepharma.com --- News for Agent · https://newsforagent.com/llms.txt